Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial - Archive ouverte HAL Access content directly
Journal Articles Lancet Oncology Year : 2016

Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(1) , (2) , (3, 4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (15) , (15) , (15) , (15) , (15) , (16) , (16)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Abstract

Background The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF V600-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated effi cacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01407426 , version 1 (02-12-2016)

Identifiers

  • HAL Id : inserm-01407426 , version 1

Cite

Paolo A. Ascierto, Grant A Mcarthur, Brigitte Dréno, Victoria A Atkinson, Gabrielle Liszkay, et al.. Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, 2016, 17, pp.1248-1260. ⟨inserm-01407426⟩
64 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More